source
- Cellectis to cut 70% of staff as it shifts focus from allogeneic CAR-T to in vivo gene editingCellectis announced that roughly seven out of ten employees will be let go as the Paris‑based biotech restructures its operations. The company previously abandoned its two clinical‑stage allogenei…
- AstraZeneca withdraws EU filing for monoclonal antibody targeting amyloidosis subsetAstraZeneca has announced that it is pulling its European marketing application for a monoclonal antibody intended for a specific subgroup of amyloidosis patients. The decision follows earlier fail…